{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T19:26:02Z","timestamp":1648927562197},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11845-019-02001-y","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T08:03:15Z","timestamp":1553760195000},"page":"1251-1259","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improvement in health status with once-daily indacaterol\/glycopyrronium 110\/50\u00a0\u03bcg in COPD patients: real-world evidence from an observational study in Ireland"],"prefix":"10.1007","volume":"188","author":[{"given":"Brian","family":"O\u2019Doherty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Molony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se\u00e1n","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"2001_CR1","unstructured":"WHO website. Chronic obstructive pulmonary disease (COPD) factsheet. Available from: \n                    http:\/\/www.who.int\/mediacentre\/factsheets\/fs315\/en\/\n                    \n                  . Accessed 16 Oct 2018"},{"key":"2001_CR2","unstructured":"WHO website. Burden of COPD. Available from: \n                    http:\/\/www.who.int\/respiratory\/copd\/burden\/en\/\n                    \n                  . \n                    http:\/\/www.who.int\/respiratory\/copd\/burden\/en\/\n                    \n                  . Accessed 16 Oct 2018"},{"key":"2001_CR3","unstructured":"WHO website. The top 10 causes of death. Available from: \n                    http:\/\/www.who.int\/mediacentre\/factsheets\/fs310\/en\/\n                    \n                  . Accessed 16 Oct 2018"},{"key":"2001_CR4","unstructured":"National Patient Safety Office website. National healthcare quality reporting system annual report 2017. Available from: \n                    http:\/\/health.gov.ie\/wp-content\/uploads\/2017\/07\/NHQRS-2017-Annual-Report.pdf\n                    \n                  . Accessed 15 Nov 2018"},{"key":"2001_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/COPD.S18181","volume":"6","author":"PW Jones","year":"2011","unstructured":"Jones PW, Price D, van der Molen T (2011) Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 6:289\u2013296. \n                    https:\/\/doi.org\/10.2147\/COPD.S18181","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2001_CR6","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011) Global strategy for the diagnosis, management and prevention of COPD. Available from: \n                    http:\/\/www.goldcopd.org\/"},{"key":"2001_CR7","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2018) Global strategy for the diagnosis, management and prevention of COPD. Available from: \n                    http:\/\/www.goldcopd.org\/\n                    \n                  . Accessed 15 Nov 2018"},{"key":"2001_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2147\/COPD.S29868","volume":"7","author":"AJ Cave","year":"2012","unstructured":"Cave AJ, Atkinson L, Tsiligianni IG, Kaplan AG (2012) Assessment of COPD wellness tools for use in primary care: an IPCRG initiative. Int J Chron Obstruct Pulmon Dis 7:447\u2013456. \n                    https:\/\/doi.org\/10.2147\/COPD.S29868","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2001_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-1-13","volume":"1","author":"T Molen van der","year":"2003","unstructured":"van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF (2003) Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 1:13","journal-title":"Health Qual Life Outcomes"},{"key":"2001_CR10","unstructured":"Ultibro Breezhaler\u2014summary of product characteristics. Novartis Pharmaceuticals UK Ltd (November 2017)"},{"issue":"3","key":"2001_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","volume":"1","author":"JA Wedzicha","year":"2013","unstructured":"Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D (2013) Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 1(3):199\u2013209. \n                    https:\/\/doi.org\/10.1016\/S2213-2600(13)70052-3","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2001_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12931-017-0622-x","volume":"18","author":"CF Vogelmeier","year":"2017","unstructured":"Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K, Cs i (2017) Efficacy and safety of direct switch to indacaterol\/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res 18(1):140. \n                    https:\/\/doi.org\/10.1186\/s12931-017-0622-x","journal-title":"Respir Res"},{"issue":"4","key":"2001_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/thoraxjnl-2014-206345","volume":"70","author":"R Buhl","year":"2015","unstructured":"Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S (2015) Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax 70(4):311\u2013319. \n                    https:\/\/doi.org\/10.1136\/thoraxjnl-2014-206345","journal-title":"Thorax"},{"issue":"11","key":"2001_CR14","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1007\/s12325-017-0626-4","volume":"34","author":"GJ Feldman","year":"2017","unstructured":"Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcazar Navarrete B (2017) Comparative efficacy of once-daily umeclidinium\/vilanterol and tiotropium\/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther 34(11):2518\u20132533. \n                    https:\/\/doi.org\/10.1007\/s12325-017-0626-4","journal-title":"Adv Ther"},{"issue":"6","key":"2001_CR15","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00408-017-0055-9","volume":"195","author":"E Kerwin","year":"2017","unstructured":"Kerwin E, Ferguson GT, Sanjar S, Goodin T, Yadao A, Fogel R, Maitra S, Sen B, Ayers T, Banerji D (2017) Dual bronchodilation with indacaterol maleate\/glycopyrronium bromide compared with umeclidinium bromide\/vilanterol in patients with moderate-to-severe COPD: results from two randomized, controlled, cross-over studies. Lung 195(6):739\u2013747. \n                    https:\/\/doi.org\/10.1007\/s00408-017-0055-9","journal-title":"Lung"},{"issue":"14","key":"2001_CR16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","volume":"371","author":"H Magnussen","year":"2014","unstructured":"Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM, Investigators W (2014) Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 371(14):1285\u20131294. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1407154","journal-title":"N Engl J Med"},{"key":"2001_CR17","unstructured":"Heinrich Worth KK, Buhl R, Cri\u00e9e C-P, Kardos P, Lossi N, Mail\u00e4nder C, Vogelmeier C (2017) ICS withdrawal and treatment with a fixed-dose LABA\/LAMA combination: the German real-life DACCORD COPD cohort. Poster AP236. Asian Pacific Society of Respirology congress, 23\u201326 November 2017, Sydney, Australia"},{"key":"2001_CR18","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.2147\/COPD.S16995","volume":"13","author":"R Buhl","year":"2018","unstructured":"Buhl R, Cri\u00e9e C-P, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H (2018) Dual bronchodilation vs triple therapy in the \u201creal-life\u201d COPD DACCORD study. Int J Chron Obstruct Pulmon Dis 13:2557\u20132568. \n                    https:\/\/doi.org\/10.2147\/COPD.S16995","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2001_CR19","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. Global strategy for the diagnosis, management and prevention of COPD. Available from: \n                    http:\/\/www.goldcopd.org\/"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-019-02001-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11845-019-02001-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-019-02001-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:26:59Z","timestamp":1585268819000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11845-019-02001-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2001"],"URL":"https:\/\/doi.org\/10.1007\/s11845-019-02001-y","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"28 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Brian O\u2019Doherty, Jane Dorman, Karen McGrath, Kevin Kelly and David Molony were involved in conduct of study and Se\u00e1n Lacey provided statistical service. Sarah Whelan, Simon Schmid and Shane Sullivan are employees of Novartis. Authors have no potential conflict of interest to declare. The authors received no compensation related to the development of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}